Financial Data and Key Metrics Changes - For Q4 2020, the company reported revenue of $2.4 million, an increase of $0.5 million compared to Q3 2020 [22] - The net loss for Q4 2020 was $4.9 million, or $1.07 per share, compared to a net loss of $6 million, or $2.90 per share, in Q4 2019 [24] - Full-year 2020 revenue was $13.3 million, up from $12.8 million in 2019, with a net loss of $12.8 million compared to $24.5 million in 2019 [26] Business Line Data and Key Metrics Changes - The revenue for Q4 2020 was primarily composed of services revenue under the Corium consulting arrangement [22] - R&D expenses for Q4 2020 were $3.1 million, while G&A expenses were $2.5 million, maintaining the same expense posture as previous years [25] Market Data and Key Metrics Changes - The ADHD market is valued at $17.5 billion, with the company believing its product can meet key advantages over existing methylphenidate-based products [18] Company Strategy and Development Direction - The company has completed a multi-phase financial restructuring, resulting in approximately $94 million in growth proceeds and the elimination of all debt [20][21] - The company aims to optimize the value of its product AZSTARYS and is exploring new assets for potential acquisition to create shareholder value [68][69] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the approval of AZSTARYS and its potential impact on the company's future [8][12] - The company believes there is a disconnect between its current market valuation and the potential value from the AZSTARYS approval [48][52] Other Important Information - The company regained its listing on the NASDAQ Capital Market in January 2021 and reported total cash of $77.6 million as of March 10, 2021 [30][31] Q&A Session Summary Question: Clarification on fully diluted shares outstanding after restructuring - The number of fully diluted shares outstanding is 38.6 million, including 9.6 million of preferred stock [36] Question: Current market cap and cash position - The current cash position is $77.6 million, with a market cap of approximately $283 million based on shares outstanding [39] Question: Commercialization plans for AZSTARYS - The company believes it has an excellent label for AZSTARYS and is confident in Corium's commercialization strategy [46] Question: Disconnect between current evaluation and potential value from AZSTARYS approval - Management encouraged investors to compare the labels of AZSTARYS with existing products to understand its potential market share [50][52] Question: Capital deployment and potential new assets - The company is looking at new assets that add value and will continue to support the development of its existing products [68][69]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (321) 939-3416 (Address of Principal Executive Offices and Zip Code) (Registrant's Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: FORM 10 ...

KemPharm, Inc. (KMPH) Q3 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright & Co., LLC Operator Good afternoon, ladies and gentlemen, and welcome to KemPharm Q3 2020 Corporate Update Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of ...

KemPharm, Inc. (KMPH) Q2 2020 Results Conference Call August 12, 2020 4:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President & CEO LaDuane Clifton - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to the KemPharm Q2 2020 Corporate Update Conference Call. At this time, all participants’ lines are in a listen-only mode. After the speakers’ presentation, there will be a quest ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inc ...

KemPharm, Inc. (KMPH) Q1 2020 Earnings Conference Call May 12, 2020 5:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President & CEO LaDuane Clifton - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to KemPharm's First Quarter 2020 Corporate Update Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identifi ...

KemPharm, Inc. (KMPH) Q3 2019 Earnings Conference Call November 14, 2019 5:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President & CEO LaDuane Clifton - CFO Rusty Johnson - Chief Business Officer Conference Call Participants Daniel Busby - RBC Capital Markets Oren Livnat - H.C. Wainwright Scott Henry - ROTH Capital Partners Operator Ladies and gentlemen, thank you for standing by and welcome to KemPharm’s Third Quarter 2019 Corporate Update. At this time, al ...